BioNTech (BNTX) R&D Day 2024 summary

Strategic vision and business evolution

• Transitioning to a multi-product oncology company, leveraging over 15 years of platform development and strong COVID-19 vaccine cash flows to fund late-stage oncology launches and R&D.

• Oncology pipeline includes 20 clinical programs, 13 in Phase II/III, and expansion into biologics manufacturing via recent acquisitions, including Biotheus.

• Strategic investments in AI, manufacturing, and M&A, such as InstaDeep and Biotheus, to accelerate clinical development and commercial infrastructure.

• Maintaining a lean, cash-generating COVID-19 franchise with over 50% market share and €17.8B in cash and investments as of Q3 2024.

• R&D investment and M&A activity increased from 2023 to 2024, with a growing cash balance and focus on late-stage oncology trials.

Oncology pipeline and late-stage programs

• Five late-stage oncology assets prioritized: BNT327 (VEGF–PD-L1 bispecific), autogene cevumeran (personalized RNA vaccine), FixVac (off-the-shelf RNA vaccine), BNT211 (Claudin-6 CAR-T), and BNT323 (HER2-ADC).

• BNT327/PM8002 positioned as a next-generation IO backbone, with strong efficacy in TNBC, NSCLC, and SCLC, and planned combinations with ADCs.

• BNT323/DB-1303 (HER2-ADC) targets endometrial and breast cancer, aiming for first oncology launch in 2026, with robust ORR and DOR data and Phase 3 trials underway.

• Claudin-6 CAR-T (BNT211) demonstrates meaningful responses in germ cell and ovarian cancers, with pivotal Phase II trials planned.

• Autogene cevumeran advancing in adjuvant settings for PDAC, CRC, and MIUC, with multiple Phase 2 trials ongoing.

Cancer vaccine platforms and clinical data

• mRNA vaccine platform differentiated by uridine chemistry, non-coding backbone, and systemic delivery, enabling strong T cell responses.

• iNeST (autogene cevumeran) and FixVac platforms show high immunogenicity, with over 75% of patients developing de novo immune responses.

• iNeST trials focus on adjuvant settings in pancreatic, colorectal, and bladder cancers, targeting minimal residual disease and high relapse risk.

• FixVac programs in head and neck and lung cancer show promising early efficacy and safety, with ongoing randomized Phase II studies.

• Combination approaches with ADCs and bispecifics are being explored to maximize efficacy and address tumor heterogeneity.